Loading organizations...
§ Private Profile · New York City, NY, USA
Biopharmaceutical company developing AMPK activators for aging-related diseases, metabolic, cardiovascular, kidney diseases.
Based in New York, New York, Amplifier Therapeutics is a clinical-stage biopharmaceutical company developing AMPK activator compounds to treat aging-related and metabolic disorders. The organization focuses on cellular energy sensors that mimic the physiological effects of fasting and exercise, advancing its lead drug candidate, ATX-304, through Phase 1b clinical trials for cardiovascular disease, kidney disease, and severe obesity. Operating as a strategic spinoff from its parent company Cambrian Bio, the firm acquired the global development and commercialization rights for its primary therapeutic asset from partner Betta Pharmaceuticals. The enterprise has secured approximately $38.18 million in total standalone venture funding to date, while its parent organization has raised over $160 million to support a broader longevity research pipeline. Amplifier Therapeutics was officially founded in 2023 by James Peyer alongside scientific founders Helena Edlund and Thomas Edlund.
Amplifier Therapeutics has raised $33.3M across 1 funding round.
Amplifier Therapeutics has raised $33.3M in total across 1 funding round.
Amplifier Therapeutics has raised $33.3M across 1 funding round. Most recently, it raised $33.3M Series A in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 18, 2023 | $33.3M Series A | Cambrian | Future Ventures, RA Capital Management | Announced |
Amplifier Therapeutics has raised $33.3M in total across 1 funding round.
Amplifier Therapeutics's investors include Cambrian, Future Ventures, RA Capital Management.